Q-omics provides the consensus-scored ARMCX3 profile across patient tissues and cancer cell-line models. ARMCX3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARMCX3 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ARMCX3 protein abundance shows 25,028 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, THCA, and PDAC as cancer lineages where ARMCX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARMCX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARMCX3 survival associations across molecular data types. ARMCX3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARMCX3 RNA expression–survival associations across cancer types. High ARMCX3 expression shows unfavorable associations in UVM, SARC and KIRP, but favorable associations in KIRC, THCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARMCX3 RNA expression.
This table summarizes ARMCX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ARMCX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARMCX3 shows lower tumor expression in LUSC, LUAD and UCEC and higher tumor expression in THCA, COAD and CHOL. The THCA box plot shows higher ARMCX3 RNA expression in tumor versus normal tissue (log2 FC = +1.176, t-test p < 0.001).
This table shows molecular features associated with ARMCX3 in patient tissues and cancer cell lines. In patient samples, ARMCX3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARMCX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and CNS.
